Mer­ck’s HIV drug do­ravirine looks sol­id — though far less stel­lar than ri­vals — in 1st PhI­II

Mer­ck’s late-stage an­tivi­ral do­ravirine (MK-1439) came through in its first Phase III study, match­ing up nice­ly against J&J’s block­buster Prezista.

The non-nu­cle­o­side re­verse tran­scrip­tase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA